Granules Life Sciences Private Limited (GLS), a wholly-owned subsidiary of Granules India Limited , has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Hyderabad facility.

"Granules Life Sciences Private Limited (GLS), a wholly owned subsidiary of Granules India Limited situated in Hyderabad, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the first inspection conducted from July 28, 2025 to Aug 01, 2025. This approval confirms the facility's compliance with FDA quality standards and regulatory requirements," the company said in an exchange filing.

The inspection, conducted from July 28 to August 1, 2025, confirmed the facility's compliance with FDA quality standards and

See Full Page